Literature DB >> 19371504

First-line pharmacotherapy approaches for generalized anxiety disorder.

Jonathan R Davidson1.   

Abstract

Many patients with generalized anxiety disorder (GAD) do not receive adequate treatment. Several classes of drugs, including benzodiazepines, azapirones, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antihistamines, alpha(2)delta Ca++ channel modulators, and atypical antipsychotics are consistently beneficial in patients with GAD. Cognitive therapy is also effective as a first-line treatment. When individualizing treatment, drug dose ranges and side effect profiles need to be considered, as well as the patient's comorbid conditions. Doses may need to be reduced for elderly or medically ill patients or those taking other medications. Doses may need to be increased for refractory cases. Common comorbid conditions with GAD include depression, alcohol or drug abuse, social anxiety disorder, and panic disorder. In patients with significant depression, an antidepressant is more likely to succeed than a benzodiazepine. Generalized anxiety disorder is a chronic illness that requires long-term treatment. Remission is attainable but can take several months, and stopping medication increases the risk of relapse within the first year of initiating treatment. Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371504     DOI: 10.4088/jcp.s.7002.05

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

Review 2.  Exercise offers anxiolytic potential: a role for stress and brain noradrenergic-galaninergic mechanisms.

Authors:  Natale R Sciolino; Philip V Holmes
Journal:  Neurosci Biobehav Rev       Date:  2012-07-05       Impact factor: 8.989

Review 3.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

4.  The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder.

Authors:  Young-Min Park; Do-Won Kim; Sangrae Kim; Chang-Hwan Im; Seung-Hwan Lee
Journal:  Psychopharmacology (Berl)       Date:  2010-11-06       Impact factor: 4.530

5.  Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety.

Authors:  Jesse W Richardson-Jones; Caryne P Craige; Thanh H Nguyen; Hank F Kung; Alain M Gardier; Alex Dranovsky; Denis J David; Bruno P Guiard; Sheryl G Beck; René Hen; E David Leonardo
Journal:  J Neurosci       Date:  2011-04-20       Impact factor: 6.167

6.  The Effect of the Low Glutamate Diet on the Reduction of Psychiatric Symptoms in Veterans With Gulf War Illness: A Pilot Randomized-Controlled Trial.

Authors:  Elizabeth T Brandley; Anna E Kirkland; Michael Baron; James N Baraniuk; Kathleen F Holton
Journal:  Front Psychiatry       Date:  2022-06-20       Impact factor: 5.435

Review 7.  Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review.

Authors:  Shaheen E Lakhan; Karen F Vieira
Journal:  Nutr J       Date:  2010-10-07       Impact factor: 3.271

8.  5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition.

Authors:  Vikas Duvvuri; Victoria B Risbrough; Walter H Kaye; Mark A Geyer
Journal:  Pharmacol Biochem Behav       Date:  2009-05-31       Impact factor: 3.533

9.  Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.

Authors:  Marina De Salas-Cansado; José M Olivares; Enrique Alvarez; Jose L Carrasco; Andoni Barrueta; Javier Rejas
Journal:  Clinicoecon Outcomes Res       Date:  2012-06-13

10.  Long-Term Citalopram Treatment Alters the Stress Responses of the Cortical Dopamine and Noradrenaline Systems: the Role of Cortical 5-HT1A Receptors.

Authors:  Fumi Kaneko; Yukie Kawahara; Yuki Kishikawa; Yuuki Hanada; Makiko Yamada; Tatsuyuki Kakuma; Hiroshi Kawahara; Akinori Nishi
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.